- Celgene: Clinical study for use of Revlimid as a first-line treatment of multiple myeloma stopped early due to significant efficacy
- Actelion: Continued strong growth for Tracleer for the first six months of 2009
- Gilead: Collaboration with Johnson & Johnson (Tibotec) to develop fix combination of Truvada and TMC278